Association Between NAT2 Polymorphisms and Prostate Cancer
Journal Title: International Journal of Cancer Management - Year 2017, Vol 10, Issue 2
Abstract
Background NAT2 enzyme involved in bioconversion of aromatic amines, heterocyclic arylamines and certain drugs into electrophilic ions that can be important initiators in tumorigenesis process. Objectives The aim of this study was to assess the possible association between NAT2 polymorphisms (857 G > A, 481 T > C, and 590 G > A) and risk of prostate cancer (PC). Methods Totally, 207 benign prostate hyperplasia (BPH) and 147 PC Iranian patients were evaluated. NAT2 genotypes were detected by restriction fragment length polymorphism (RFLP). Multiple logistic regression models were used to estimate the odds ratios for the association between presence of each genotype and developing PC. Results For NAT2 G857A, the frequency of AA and AG genotypes was lower among PC patients compared to those without it (1.01% vs. 0 and 55.88% vs. 54.55%, respectively; P = 0.7). For NAT2 T481c, the odds ratios for the association of TT and CT genotypes with PC were 0.65 and 0.55, respectively, which were not statistically significant (P = 0.5 and P = 0.09, respectively). For NAT2 G590a, both AA (11.11% vs. 12.87%) and AG (45.83% vs. 52.48%) genotypes were significantly more common among PC patients compared to BPC patients (P = 0.008). However, none of the relevant odds ratios were statistically significant (OR = 2.2, P = 0.2 and OR = 1.72, P = 0.1, respectively). Among PC patients, CT genotype of T481C caused more than 4-fold significant increase in the risk of developing advanced stages of PC. Conclusions Our study represented credible evidence that carrying G857A, G590A and T481C polymorphisms of NAT2 may not affect developing PC, its grading or invasion, but heterozygote genotype of T481C polymorphism (Rapid acetylator) can be associated with more advanced stages of cancer earlier in life. Further longitudinal studies with larger sample sizes are needed to more precisely assess the genetic risk factors of PC.
Authors and Affiliations
Mandana Hasanzad, Seyed Amir Mohsen Ziaei, Vahideh Montazeri, Mahdi Afshari, Seyed Hamid Jamaldini, Mahdieh Imani, Mahshid Sattari, Leila Hashemian, Seyed Rouhollah Kalantar Moaetamed, Mohammad Samzadeh
Keywords
Related Articles
- EP ID EP237298
- DOI 10.5812/ijcp.5716
- Views 79
- Downloads 0
Cancer Stem Cell’s Potential Clinical Implications
Context: To date, CSCs have been identified in a variety of hematopoietic and solid tumors. Applying CSC in clinical implication still depends on future studies to remove complexities including CSC heterogeneity and CSC...
A Survey in the Basal Like Breast Carcinoma Phenotype in North East of Iran
Background: Breast carcinoma is not a homogenous disease. It is divided into 5 pathological subtypes of luminal1, luminal2, strongly Her2 positive, basal like, and normal breast like. Basal like breast carcinoma that acc...
Immunohistochemical Study of HER2/neu Expression in Colorectal Cancer and its Relation to other Clinicopathological Criteria and Prognostic Factors
Background: Human epidermal growth factor receptor 2 (HER2) overexpression and amplification have been studied as a therapeutic and prognostic target in a number of tumors although conflicting data exist about the incide...
The Effect of Para Aortic Lymph Node Dissection in Staging and Complete Cytoreductive Surgery of Ovarian Cancer
Objective: Lymphatic spread is a common feature of ovarian cancer both in early and advanced stages of the disease. There is also a controversial problem of the impact of para-aortic lymph node dissection between gynecol...
Selective Cytotoxicity and Apoptosis-Induction of Cyrtopodion scabrum Extract Against Digestive Cancer Cell Lines
Background: Cancer is one of the major threatening factors of human health worldwide. Unfortunately, chemotherapy, the powerful arm of cancer therapy, is accompanied with many side effects, so alternative treatments with...